My ePortfolio Register   

Comment: Niraparib for ovarian cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 830

Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium

Dr De Azambuja reviews data released at ESMO 2016 relating to the use of PARP inhibitor niraparib in platinum-sensitive recurrent ovarian cancer.

Read the news story or watch the interview or press conference with the investigator himself, Dr Mansoor Raza Mirza, for more.


Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence